Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).
Abroad (travel likely)RecruitingPHASE4
Conditions
Acute Myeloid Leukemia · Newly Diagnosed · Chemotherapy Effect
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Study leads
Yuanzhong Chen, MD
Study Director
Fujian Institute of Haematology, Fujian Medical University Union Hospital